TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Nicotine Vaccination and Nicotinic Receptor Occupancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Current smoker who smokes at least 10-25 cigarettes a day~* Good general health~Exclusion Criteria:~* Subjects with a pacemaker or other ferromagnetic material in body.~* Prior exposure to NicVAX or any other nicotine vaccine.~* Use of systemic steroids or other immunosuppressive agent~* History of significant neurological, cardiovascular, hepatic, endocrine, renal, liver, psychiatric or thyroid illness~* Cancer or cancer treatment in last 5 years~* HIV infection~* Use of varenicline (Chantix), bupropion (Wellbutrin, Zyban), mecamylamine (Inversin), within 30 days prior to administration of NicVAX and for the duration of the study.~* Inability to fulfill all visits and examination procedures for approximately 20 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Smoker (Type: EXPERIMENTAL): There is only one arm to the study. All subjects will receive NicVax, \[123I\]5-I-A-85380,and Nicotine bitartrate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent provided.~* Males or females, Aged 18-75 years.~* Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.~* Had completely resected pathological confirmed stage IIA-IIIA NSCLC.~* EGFR activating mutation in exon 19 or 21.~* Patient who can start the investigational therapy within 3-6 weeks after the complete resection.~* ECOG performance status of 0-1.~* Had a life expectancy of 12 weeks or more.~* Adequate hematological function, adequate liver function and renal function.~* Female patients, except those who are postmenopausal or surgically sterilized, must have a negative pre-study serum or urine pregnancy test.~Exclusion Criteria:~* Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).~* Inability to comply with protocol or study procedures.~* Had a history another malignancy in the last 5 years with the exception of cured basal cell carcinoma of the skin, cured in situ carcinoma of the uterine cervix and cured epithelial carcinoma of the bladder.~* Any evidence confirmed tumor recurrence before investigational therapy.~* Known severe hypersensitivity to icotinib or any of the excipients of this product.~* Evidence of clinically active interstitial lung disease.~* Eye inflammation not fully controlled or conditions predisposing the subject to this.~* Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).~* Known human immunodeficiency virus (HIV) infection.~* Pregnancy or breast-feeding women.~* Ingredients mixed with small cell lung cancer patients.~* History of neurologic or psychiatric disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Icotinib 125 mg three times daily (375 mg per day) orally for 12 months.
- Observation group (Type: NO_INTERVENTION): Observation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Records of men aged \>18 years with an index PDE5 inhibitor (sildenafil, tadalafil or vardenafil) prescription between January 1st, 1999, and June 30th, 2008~* no prior PDE5 inhibitor prescription before the index prescription~* continuous enrolment with medical history for ≥60 months prior to the index prescription date~Exclusion Criteria:~* Records of female subjects and any male subjects not meeting the inclusion criteria will be excluded~* A subject can only be selected once independent of the assignment to the target or the control populations.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PDE5 inhibitor prescription (Type: None): None
- Age-matched Control (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tissue and Plasma Pharmacokinetics of Cefazolin in Antibiotic Prophylaxis in Bariatric Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged \> 18 years.~* BMI ≥ 40 and ≤ 65 kg/m2.~* The patient has given informed consent in writing.~Exclusion Criteria:~* Age less than 18 years and above 70 years.~* Major Trust.~* Pregnancy.~* Moderate to severe renal insufficiency or clearance creatinine clearance \<60 ml / min~* Hypersensitivity to cephalosporins and beta-lactams.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cefazoline (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months~* Inadequate response or limiting side effects with anticholinergics for the treatment of OAB~Exclusion Criteria:~* Overactive Bladder caused by neurological condition~* Patient has predominance of stress incontinence~* History or evidence of pelvic or urological abnormality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- onabotulinumtoxinA (Type: EXPERIMENTAL): OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
- placebo/onabotulinumtoxinA (Type: OTHER): Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Danhong Injection in the Treatment of Unstable Angina Pectoris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male inpatients.~* Age: 35 - 75 years.~* Patients with clinical diagnosis of unstable stable angina according to China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association, including one of the following conditions.~* Clinical diagnosis of Xueyu Zheng (Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales of Xueyu Zheng in UA ≥ 15. The Chinese medicine symptoms scales of Xueyu Zheng is a 6-item questionnaire including the symtoms as following: (1)chest pain-10, (2)chest distress-10, (3) palpitation-5, (4)purple or dark lip-5, (5) purple or dark tongue-5, (6) unsmooth pulse-5.~* Patient is willing to participate voluntarily and to sign a written patient informed consent.~Exclusion Criteria:~* Patients with severe heart failure (EF\<35%);~* Patients with history of infection, fever, trauma, surgery(exclude PCI) and inflammation in the past month;~* Patients with active tuberculosis or rheumatological disorders;~* Patients with renal dysfunction (Male: CCr\>2.5mg/dl; Female: CCr\>2.0mg/dl);~* Patients with liver dysfunction (any value of serum aminotransferase more than triple normal value);~* Patients with history of hematopoietic system diseases;~* Patients with mental disorder;~* Patients with history of drug-induced bleeding or history of bleeding caused by warfarin;~* Patients with malignant tumor;~* Patients with history of organ transplant;~* Woman with pregnancy, lactation or positive result of pregnancy test;~* Patients who is participating in other trials or has been participated in other trials in recent 3 months;~* Patients who were unable to participate in the study as judged by investigator.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Danhong injection (Type: EXPERIMENTAL): Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years;~* Planned treatment with regular paclitaxel-based chemotherapy for any indication and with any dose~Exclusion Criteria:~* Prior treatment with a paclitaxel-based regimen;~* Inability to orally ingest cetirizine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clemastine group (Type: None): Subjects receiving standard of care treatment with paclitaxel either as monotherapy or as part of a combination for any standard of care oncologic indication. Subjects received a paclitaxel premedication regimen containing dexamethasone 10 mg IV and clemastine 2 mg IV
- Cetirizine group (Type: None): Subjects receiving standard of care treatment with paclitaxel either as monotherapy or as part of a combination for any standard of care oncologic indication. Subjects received a paclitaxel premedication regimen containing dexamethasone 10 mg IV and cetirizine 10 mg PO

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age.~* Have a history of redness relief drops use or expressed a desire to use drops for redness relief, within the last 6 months.~* Have ocular health within normal limits including a calculated best-corrected visual acuity of 0.3 logarithm of the minimum angle of resolution (logMAR) or better in each eye, as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart.~Exclusion Criteria:~* Any ocular/systemic health problems.~* Use of any disallowed medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brimonidine Tartrate (Type: EXPERIMENTAL): Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
- Brimonidine Tartrate Vehicle (Type: PLACEBO_COMPARATOR): Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Four-Week Study to Measure the Effectiveness of an Experimental Mouthwash Used After Teeth Cleaning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females at least 18 years of age and in good general health.~* Must display adequate oral hygiene (i.e., brush teeth daily and exhibit no signs of oral neglect).~* Volunteers must read, sign, and receive a copy of the Informed Consent Form after the nature of the study has been fully explained.~* Must be willing to use the products according to instructions and be available for appointments.~* Baseline dental measurements meet protocol-specified criteria.~* Willingness to refrain from using all oral hygiene procedures within 12-18 hours prior to each visit.~* Refrain from eating, drinking or smoking for four hours prior to each visit.~Exclusion Criteria:~* Lip, tongue, or other form of oral piercing.~* Fixed or removable orthodontic appliance (such as bridges, braces or dentures).~* Pregnancy or breast-feeding at any time during the trial.~* Any medical, dental or psychiatric condition, abnormality or history, or use of any product or drug, that (per protocol or in the opinion of the investigator) may increase the risk to the subject associated with trial participation or investigational product administration, or interfere with the interpretation of trial results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.15% ethyl lauroyl arginate HCl-containing mouthrinse (Type: EXPERIMENTAL): Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 0.15% ethyl lauroyl arginate HCl-containing mouthrinse (19415-154-1) for 30 seconds - repeat twice daily for four weeks.
- 5% hydroalcohol mouthrinse (Type: SHAM_COMPARATOR): Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 5% hydroalcohol mouthrinse (W002194-0221P) for 30 seconds - repeat twice daily for four weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatients with Diagnostic and Statistical Manual of Mental Disorders 4th Edition Text Revision (DSM-IV TR) diagnosis of schizophrenia, schizophreniform or schizoaffective disorder~* PANSS total score at baseline \> 75, at least two PANSS psychosis items ≥ 4, Clinical Global Impression of severity score moderately ill or more (≥4)~* Increase in the level of care (outpatient care to day clinic or inpatient care)~Exclusion Criteria:~* contraindication to study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- initial olanzapine (Type: ACTIVE_COMPARATOR): None
- initial amisulpride (Type: ACTIVE_COMPARATOR): None
- early responders (Type: ACTIVE_COMPARATOR): None
- early non-responders switched (Type: ACTIVE_COMPARATOR): None
- ealy non-responders non-switched (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with mixed dyslipidemia (trigylcerides, \> or = to 150 mg/dL to \< 400 mg/dL; HDL-C \< 40 mg/dL for males, \< 50 mg/dL for females; LDL-C, \> or = to 130 mg/dL).~* Subjects must agree to use adequate birth control methods and to adhere to the American Heart Association (AHA) Diet.~Exclusion Criteria:~* Subjects with unstable or uncontrolled medical conditions considered inappropriate in a clinical trial.~* Subjects with an unstable dose of medications or receiving Coumadin, oral, intravenous or intramuscular cyclosporine, statins, or certain other medications.~* Women who are pregnant or plan on becoming pregnant, or women who are lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-335 + atorvastatin + ezetimibe (Type: ACTIVE_COMPARATOR): None
- Placebo + atorvastatin + ezetimibe (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. written informed consent;~2. ≥18 years of age;~3. a bacterial infection of the skin with a lesion size area of at least 75 cm2;~4. a major cutaneous abscess, cellulitis/erysipelas, and/or wound infections;~5. the presence of purulent or seropurulent drainage or at least three signs and symptoms of infection (discharge, erythema, swelling, warmth, or pain).~Exclusion Criteria:~1. severely impaired arterial blood supply such that amputation of the infected anatomical site is likely;~2. infected diabetic foot ulcers;~3. infected decubitus ulcers;~4. necrotizing fasciitis or gangrene;~5. uncomplicated skin or skin structure infection;~6. infections associated with a prosthetic device;~7. suspected or confirmed osteomyelitis;~8. conditions requiring systemic anti-microbial treatment, prophylaxis, or suppression therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iclaprim (Type: EXPERIMENTAL): iclaprim 80 mg intravenous every 12 hours
- vancomycin (Type: ACTIVE_COMPARATOR): vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject and/or parent or legal guardian must be able to understand and provide informed consent/assent;~* Candidate for or recipient of: heart, liver, heart with liver, small intestine, liver with small intestine, or kidney; and~* Subject enrolled within 3 years of transplant.~Exclusion Criteria:~* Previous diagnosis of PTLD;~* Transplant recipients of lung alone, or in combination with an eligible organ type;~* Pancreas transplantation with the exception of 'en bloc' transplant in combined liver and small intestine multivisceral transplantation;~* Any combination other than listed in inclusion criteria;~* History of any previous solid organ, stem cell, or bone marrow transplantation;~* Inability or unwillingness of the legal guardian and/or the subject to comply with the study protocol.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Subjects Enrolled Pre-Transplant (Type: None): Subjects (N=approximately 357) Enrolled Pre-Transplant~* Subjects with evidence of EBV infection prior to transplant~* Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant
- Subjects Enrolled Post-Transplant (Type: None): Subjects (N=approximately 588) Enrolled 3 Yrs Post-Transplant~* Subjects with evidence of EBV infection prior to transplant~* Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete